Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee
19 affiliations
- 1Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
- 2Service d’Hématologie clinique et Thérapie cellulaire, Hôpital Saint-Antoine, APHP, Paris, France
- 3EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France
- 4Centre de Thérapie Cellulaire, Département de Biologie du Cancer, Institut Paoli-Calmettes Comprehensive Cancer Centre, Inserm-Aix-Marseille Université-AP-HM-IPC, CBT-1409 Marseille, France
- 5Community Relations, Marketing & Communications, EBMT Executive Office, Barcelona, Spain
- 6EBMT Chief Medical Officer, Executive Office, Barcelona, Spain
- 7Advocacy and Quality of Care, EBMT Executive Office, Barcelona, Spain
- 8EBMT Executive Office, Barcelona, Spain
- 9Hematology and Cellular Therapy Unit. IRCCS Azienda Ospedaliera Metropolitana. Plesso Ospedale Policlinico San Martino, Genova, Italy
- 10Barts Health NHS Trust, London, UK
- 11Department of Haematology, King’s College Hospital NHS Foundation Trust, London, UK
- 12Willem-Alexander Children’s Hospital, Department of Paediatrics, Leiden University Medical Center, Leiden, the Netherlands
- 13Department of Haematology, University College London Hospitals, London, UK
- 14University College London, London, UK
- 15Hematology and Hematopoietic Transplant Unit, Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati (A.O.R.N. Giuseppe Moscati), Avellino, Italy
- 16Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- 17Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
- 18Centre Hospitalier Universitaire de Lille, University of Lille, INSERM U1286, Infinite, Lille, 59000 France
- 19IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Haematology and Bone Marrow Transplantation, Milano, Italy
Abstract
Hematopoietic cell transplantation, cellular and gene therapies, and (CAR)-T cells have revolutionized outcomes in hematologic disorders. However, major disparities persist in their availability, accessibility, and affordability, particularly in low- and middle-income countries (LMICs). The EBMT Global Committee aims to address these inequalities. A structured survey was distributed to EBMT members to identify regional and thematic priorities, assess current infrastructure, and assess willingness to contribute to global initiatives. Responses were analyzed descriptively and served as the basis for the current statement paper. A total of 145 responses from 43 countries were collected. Most respondents (67.1%) reported working in JACIE- or FACT-accredited centers. The highest priority regions for EBMT outreach were Eastern Europe (non-EU) (43.9%), Latin America (38.2%), and Africa (33.5%), followed by the Middle East (29.5%). The leading thematic priorities were education and training (74.3%), scientific collaboration (56.0%), and registry development (43.4%). Most respondents expressed willingness to actively contribute, particularly in educational activities (59.7%). Qualitative responses emphasized the need for practical guidelines, mentorship programs, telemedicine, virtual discussion/clinical rounds on difficult cases, and support for LMIC capacity building. The EBMT community strongly supports an expanded global role focused on education, capacity building, and collaboration in underserved regions.
Related
- Syndrome-oriented CNS infectious complications after hematopoietic stem-cell transplantation and CAR T-cell therapy, part 1—viral encephalitis, meningitis, and myelitis: recommendations from the Practice Harmonization & Guidelines Committee of the EBMT
- PREDICTIVE FACTORS FOR HEMATOPOIETIC STEM CELL MOBILIZATION IN AUTOLOGOUS TRANSPLANTATION: DEFINING A PERIPHERAL CD34+ CUTOFF FOR SINGLE-SESSION SUCCESS
- Artificial intelligence in cardiology for non-experts: decoding key terms and understanding machine learning methodologies. A Scientific Statement of the ESC Working Group on e-Cardiology, the European Heart Rhythm Association (EHRA), the Association for Acute CardioVascular Care (ACVC), the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI), the European Association of Preventive Cardiology (EAPC), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, the ESC Regulatory Affairs Committee, and the ESC Digital Cardiology and Artificial Intelligence Committee
- Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2026–2027
- Defining Success in Ptosis Surgery: Outcome Heterogeneity and Priorities for Standardization
BibTeX
@article{nagler2026defining,
title = {{Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee}},
author = {Arnon Nagler and Norbert Claude Gorin and Christian Chabannon and Guillermo Puigventós and Romée Heemskerk and Isabel Sánchez-Ortega and Tuula Rintala and Yann Mahé and Emanuele Angelucci and Silvia Montoto and Michelle Kenyon and Hilda Mekelenkamp and Donal P. McLornan and Antonio M. Risitano and Mette Hazenberg and Anna Sureda and Ibrahim Yakoub Agha and Annalisa Ruggeri and Fabio Ciceri and Raffaella Greco},
journal = {Bone Marrow Transplantation},
year = {2026},
month = aug,
doi = {10.1038/s41409-026-03008-7},
url = {https://doi.org/10.1038/s41409-026-03008-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from EBMT Global Committee
AU - Arnon Nagler
AU - Norbert Claude Gorin
AU - Christian Chabannon
AU - Guillermo Puigventós
AU - Romée Heemskerk
AU - Isabel Sánchez-Ortega
AU - Tuula Rintala
AU - Yann Mahé
AU - Emanuele Angelucci
AU - Silvia Montoto
AU - Michelle Kenyon
AU - Hilda Mekelenkamp
AU - Donal P. McLornan
AU - Antonio M. Risitano
AU - Mette Hazenberg
AU - Anna Sureda
AU - Ibrahim Yakoub Agha
AU - Annalisa Ruggeri
AU - Fabio Ciceri
AU - Raffaella Greco
PY - 2026
DA - 2026/08/11
JO - Bone Marrow Transplantation
DO - 10.1038/s41409-026-03008-7
UR - https://doi.org/10.1038/s41409-026-03008-7
AB - Hematopoietic cell transplantation, cellular and gene therapies, and (CAR)-T cells have revolutionized outcomes in hematologic disorders. However, major disparities persist in their availability, accessibility, and affordability, particularly in low- and middle-income countries (LMICs). The EBMT Global Committee aims to address these inequalities. A structured survey was distributed to EBMT members to identify regional and thematic priorities, assess current infrastructure, and assess willingness to contribute to global initiatives. Responses were analyzed descriptively and served as the basis for the current statement paper. A total of 145 responses from 43 countries were collected. Most respondents (67.1%) reported working in JACIE- or FACT-accredited centers. The highest priority regions for EBMT outreach were Eastern Europe (non-EU) (43.9%), Latin America (38.2%), and Africa (33.5%), followed by the Middle East (29.5%). The leading thematic priorities were education and training (74.3%), scientific collaboration (56.0%), and registry development (43.4%). Most respondents expressed willingness to actively contribute, particularly in educational activities (59.7%). Qualitative responses emphasized the need for practical guidelines, mentorship programs, telemedicine, virtual discussion/clinical rounds on difficult cases, and support for LMIC capacity building. The EBMT community strongly supports an expanded global role focused on education, capacity building, and collaboration in underserved regions.
SN - 0268-3369
SN - 1476-5365
ER -